RxDoctor Payments Data

Joshua Wang, MD

Psychiatry · Dallas, TXNPI 1083842322

Payments from drug & device makers

$3,960in general payments, 2019–2025

Across 183 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$720
  • AbbVie$658
  • Otsuka America Pharmaceutical, Inc.$513
  • E.r. Squibb & Sons, L.L.C.$381
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$314
  • Supernus Pharmaceuticals, Inc.$313
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,82397%
  • Education$1363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,960 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$12,593
Medicare patients
68
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate96$287,957
Invega TrinzaPaliperidone Palmitate27$241,065
VraylarCariprazine Hcl77$123,128
RexultiBrexpiprazole39$87,029
IngrezzaValbenazine Tosylate11$76,312
AustedoDeutetrabenazine11$74,141
Abilify MaintenaAripiprazole21$57,099
LybalviOlanzapine/Samidorphan Malate14$25,388
Aripiprazole141$23,925
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$11,524
Paliperidone ErPaliperidone43$9,622
Clozapine79$7,406
Quetiapine Fumarate227$7,351
Divalproex Sodium48$6,367
Oxcarbazepine84$6,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$152$529,022123 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$513$144,12860 claims
AbbVieVraylar$658$123,12877 claims
Neurocrine Biosciences, Inc.Ingrezza$221$76,31211 claims
Teva Pharmaceuticals USA, Inc.Austedo$262$74,14111 claims
Alkermes, Inc.Lybalvi$720$25,38814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →